Showing 971-980 of 10590 results for "".
Navigating Treatment Sequencing After Frontline Treatment Failure in CLL
https://reachmd.com/programs/cme/navigating-treatment-sequencing-after-frontline-treatment-failure-in-cll/39260/Dr. Jennifer Brown discusses CLL treatment sequencing after frontline failure, including resistance vs intolerance, MRD-guided strategies, and second-line therapy decisions.Personalizing First-Line Therapy for CLL
https://reachmd.com/programs/cme/personalizing-first-line-therapy-for-cll/39262/Experts explore first-line therapy selection in CLL, including biomarker testing, time-limited vs continuous regimens, safety profiles, and recent trial data.From Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
https://reachmd.com/programs/cme/from-late-line-rescue-to-early-line-option-the-potential-for-bispecific-antibodies-in-multiple-myeloma/49264/Explore how bispecific antibodies are moving earlier in the treatment paradigm of multiple myeloma, supported by pivotal data showing improved patient outcomes.Pruritus In PN and AD: Challenge How You Manage Itch
https://reachmd.com/programs/cme/pruritus-in-pn-and-ad-challenge-how-you-manage-itch/36304/Use validated assessment tools to prioritize and measure itch in prurigo nodularis and atopic dermatitis in an interactive CME escape room.Earlier Action, Lasting Impact: Closing the LDL-C Gap in Patients Without a Prior MACE
https://reachmd.com/programs/cme/earlier-action-lasting-impact-closing-the-ldl-c-gap-in-patients-without-a-prior-mace/39957/Experts review strategies for aggressive LDL lowering in high-risk patients without prior MI or stroke, highlighting updated targets and VESALIUS-CV data.Emerging Focus in NAION: Sharpening Diagnostic Precision for Tomorrow’s Treatments
https://reachmd.com/programs/cme/emerging-focus-in-naion-sharpening-diagnostic-precision-for-tomorrows-treatments/49222/Explore diagnostic strategies and evolving therapeutic data in NAION to improve acute management, differential diagnosis, and referral readiness.Highlighting the Current Status and Future of Theranostics
https://reachmd.com/programs/project-oncology/highlighting-the-current-status-and-future-of-theranostics/24497/What should we know about theranostics? Tune in.Uncovering the Disease Burden of Untreated Pediatric TK2 Deficiency
https://reachmd.com/programs/clinicians-roundtable/disease-burden-of-untreated-pediatric-tk2-deficiency/37634/How fast does thymidine kinase 2 deficiency (TK2d) progress without intervention? That’s the question explored by the largest dataset to date on untreated pediatric-onset TK2d, and the results reveal a median survival of just 2.6 years from symptom onset. Additionally, more than 80% lost at least onStanford Surgeons Perform First Beating-Heart Procedure
https://reachmd.com/programs/heart-matters/stanford-surgeons-perform-first-beating-heart-procedure/15271/Tune into this episode for more information on the first-of-its-kind beating-heart procedure from Stanford School of Medicine.What We Learned from 2020 to Stay Healthy in 2021
https://reachmd.com/programs/nutritionedge/what-we-learned-from-2020-to-stay-healthy-in-2021/12139/What are some of the key takeaways from a year none of us could have imagined?